Amgen Inc. with ticker code (AMGN) have now 23 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $380.00 and $170.00 calculating the mean target share price we have $318.72. (at the time of writing). Given that the stocks previous close was at $305.99 this indicates there is a potential upside of 4.2%. It’s also worth noting that there is a 50 day moving average of $294.24 and the 200 day moving average is $283.19. The market cap for the company is 166.24B. The stock price is currently at: $309.89 USD
The potential market cap would be $173,151,703,320 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 44.27, revenue per share of $55.15 and a 4.88% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
